Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2020 07:00 ET | Source: Kamada Ltd.

Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Product

Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s ResponsibilityKedrion is...
March 11, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs

Kamada Plans to Utilize its Hyper-Immunoglobulin (IgG) Platform Technology to Develop an Anti-Corona (COVID-19) Immunoglobulin as a Potential Therapy for Severely Ill Coronavirus Patients Kamada is...
February 26, 2020 09:30 ET | Source: Kamada Ltd.

Kamada Files Annual Report for the Year Ended December 31, 2019

REHOVOT, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F...
February 12, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2019

Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018Adjusted EBITDA for Fiscal 2019 was $28.5...
February 05, 2020 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020

REHOVOT, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...
January 21, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund

REHOVOT, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities...
January 07, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance

Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company’s Prior Revenue Guidance Company Expects Full-Year 2020 Total Revenue to be Between $132...
December 16, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in...
December 09, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product

Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023Based on current market sales...
December 02, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel

REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company,...